Amazon Web Services introduced Amazon Bio Discovery, an agentic AI system intended to accelerate antibody discovery by coordinating foundation-model selection, candidate evaluation, and routing top designs to integrated lab partners. The platform focuses first on antibodies and integrates a benchmark dataset to screen for manufacturability and stability. Amazon says the workflow supports a lab-in-the-loop cycle: the AI agent selects models, generates candidates, and sends prioritized molecules to partner labs such as Twist and Ginkgo Bioworks for synthesis and testing. Early examples cited include design of nearly 300,000 antibodies and rapid testing turnaround for the most promising subset. The move reflects how cloud providers are extending into drug R&D operations as enterprises demand faster iteration loops without requiring scientists to build complex AI infrastructure. It also intensifies competition among protein characterization CROs and discovery platforms. For biotech leaders, the operational question is how to benchmark performance, manage data governance, and translate computational candidates into predictable experimental success—areas where Amazon positions the platform as reducing coordination friction across partners. The launch expands beyond static model access by adding a task-oriented agent and a partner orchestration layer, which may shorten discovery cycles when paired with standardized experimental pipelines.